| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c43c4b973f765bdaa7538fe18f3fa24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_267aa3a9936d7ccb0a8c53aecfe294d6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2011-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16fdb14546f51468eaa6524ca65fdd88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49c9e11b1dd376ee5d5cf86839695850 |
| publicationDate |
2011-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011286983-A1 |
| titleOfInvention |
Long lasting drug formulations |
| abstract |
The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9670284-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9127084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015118187-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014271675-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9687564-B2 |
| priorityDate |
2006-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |